- Home
- GAME vs ACXP Comparison
GAME vs ACXP Comparison
Compare GAME & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- ACXP
- Stock Information
- Founded
- GAME 2011
- ACXP 2017
- Country
- GAME United States
- ACXP United States
- Employees
- GAME N/A
- ACXP N/A
- Industry
- GAME
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- ACXP Health Care
- Exchange
- GAME Nasdaq
- ACXP Nasdaq
- Market Cap
- GAME 27.2M
- ACXP 8.4M
- IPO Year
- GAME 2009
- ACXP 2021
- Fundamental
- Price
- GAME $0.89
- ACXP $0.49
- Analyst Decision
- GAME Strong Buy
- ACXP Strong Buy
- Analyst Count
- GAME 3
- ACXP 2
- Target Price
- GAME $3.67
- ACXP $10.00
- AVG Volume (30 Days)
- GAME 475.7K
- ACXP 18.6M
- Earning Date
- GAME 08-13-2025
- ACXP 08-08-2025
- Dividend Yield
- GAME N/A
- ACXP N/A
- EPS Growth
- GAME N/A
- ACXP N/A
- EPS
- GAME N/A
- ACXP N/A
- Revenue
- GAME $99,579,536.00
- ACXP N/A
- Revenue This Year
- GAME $6.08
- ACXP N/A
- Revenue Next Year
- GAME $21.94
- ACXP N/A
- P/E Ratio
- GAME N/A
- ACXP N/A
- Revenue Growth
- GAME 77.06
- ACXP N/A
- 52 Week Low
- GAME $0.50
- ACXP $0.30
- 52 Week High
- GAME $1.37
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- GAME 62.88
- ACXP 51.70
- Support Level
- GAME $0.73
- ACXP $0.46
- Resistance Level
- GAME $0.97
- ACXP $0.56
- Average True Range (ATR)
- GAME 0.07
- ACXP 0.10
- MACD
- GAME 0.01
- ACXP -0.01
- Stochastic Oscillator
- GAME 82.72
- ACXP 25.55
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.